B
BeyondSpring Inc.
BYSICIK 0001677940NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-1.01M
Total Assets
$25.93M
Equity
$-32.16M
Shares Out
41.12M
Op. Cash Flow
$-19.77M
Business
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company developing innovative therapies for patients with high unmet medical needs, primarily in oncology. It develops Plinabulin, a first-in-class small molecule immunomodulating microtubule‑binding agent studied as a direct anti-cancer therapy and for prevention of chemotherapy‑induced neutropenia, and advances preclinical small‑molecule immune agents (BPI‑002, BPI‑003, BPI‑004) while holding an equity stake in SEED Therapeutics. Key business areas include Plinabulin clinical development and commercialization, discovery and preclinical immuno‑oncology programs, and SEED’s targeted protein degradation platform and collaborations. The company conducts global clinical trials and pursues commercialization through regional partnerships and co‑development arrangements, with operations and studies spanning the U.S., China and other international sites.
Summary from filing dated 2025-03-27
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | |
| Research and development | −4 | −3 | −7 | |
| General and administrative | −5 | −6 | −8 | |
| Loss from operations | −9 | −9 | −15 | |
| Foreign exchange gain (loss), net | 165,000 | −96,000 | −128,000 | |
| Interest income | 78,000 | 59,000 | 322,000 | |
| Other income, net | 77,000 | 22,000 | 964,000 | |
| Loss before income tax | −9 | −9 | −14 | |
| Income tax expenses | −90,000 | −96,000 | −92,000 | |
| Net loss from continuing operations | −9 | −9 | −14 | |
| Loss from discontinued operations | −12 | −8 | −8 | |
| Gain on disposal of discontinued operations | 7 | 0 | — | |
| Income tax expenses | 0 | 0 | −14,000 | |
| Net loss from discontinued operations | −6 | −8 | −8 | |
| Net loss | −14 | −17 | −22 | |
| Less: Net loss attributable to noncontrolling interests from continuing operations | −242,000 | −388,000 | −922,000 | |
| Less: Net loss attributable to noncontrolling interests from discontinued operations | −13 | −5 | 0 | |
| Net loss attributable to BeyondSpring Inc. | −1 | −11 | −21 | |
| Continuing operations (in dollars per share) | −0.21 | −0.21 | −0.34 | |
| Discontinued operations (in dollars per share) | — | −0.07 | −0.2 | |
| Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share (in dollars per share) | 0.19 | — | — | |
| Basic and diluted earnings (loss) per share (in dollars per share) | −0.02 | −0.28 | −0.54 | |
| Basic and diluted (in shares) | 40 | 40 | 39 | |
| Comprehensive loss | −15 | −16 | −21 | |
| Comprehensive loss attributable to BeyondSpring Inc. | −2 | −11 | −21 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 8 | 3 | 5 | — | |
| Short-term investments | 5 | 0 | — | — | |
| Advances to suppliers | 227,000 | 240,000 | 292,000 | — | |
| Prepaid expenses and other current assets | 71,000 | 68,000 | 168,000 | — | |
| Current assets of discontinued operations | 8 | 25 | 3 | — | |
| Total current assets | 21 | 29 | 18 | — | |
| Property and equipment, net | 166,000 | 239,000 | 317,000 | — | |
| Operating right-of-use assets | 305,000 | 513,000 | 730,000 | — | |
| Other noncurrent assets | 224,000 | 213,000 | 123,000 | — | |
| Noncurrent assets of discontinued operations | 4 | 5 | 5 | — | |
| Total noncurrent assets | 5 | 6 | 6 | — | |
| Total assets | 26 | 34 | 25 | — | |
| Accounts payable | 363,000 | 295,000 | 561,000 | — | |
| Accrued expenses | 938,000 | 840,000 | 2 | — | |
| Current portion of operating lease liabilities | 320,000 | 282,000 | 258,000 | — | |
| Other current liabilities | 822,000 | 780,000 | 1 | — | |
| Current liabilities of discontinued operations | 11 | 9 | 4 | — | |
| Total current liabilities | 14 | 11 | 8 | — | |
| Operating lease liabilities | 0 | 307,000 | 589,000 | — | |
| Deferred revenue | 29 | 27 | 28 | — | |
| Other noncurrent liabilities | 4 | 4 | 4 | — | |
| Noncurrent liabilities of discontinued operations | 4 | 6 | 8 | — | |
| Total noncurrent liabilities | 36 | 38 | 40 | — | |
| Total liabilities | 50 | 49 | 48 | — | |
| Commitments and Contingencies | — | — | — | — | |
| Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 40,316,320 and 41,122,320 shares issued and outstanding as of December 31, 2024 and 2025, respectively) | 4,000 | 4,000 | 4,000 | — | |
| Additional paid-in capital | 376 | 373 | 369 | — | |
| Accumulated deficit | −408 | −407 | −396 | — | |
| Accumulated other comprehensive income | 602,000 | 1 | 894,000 | — | |
| Total BeyondSpring Inc.s shareholders deficit | −32 | −33 | −27 | — | |
| Noncontrolling interests | 8 | 19 | −9 | — | |
| Total shareholders deficit | −24 | −14 | −35 | −14 | |
| Total liabilities and shareholders deficit | 26 | 34 | 25 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Depreciation expenses | 87,000 | 285,000 | 302,000 | |
| Share-based compensation | 722,000 | 2 | 770,000 | |
| Non-cash operating lease expenses | 747,000 | 702,000 | 1 | |
| Unrealized gain on short-term investments | 0 | −3,000 | 4,000 | |
| Gain on sale of subsidiary interests | −7 | 0 | — | |
| Short-term investments | 254,000 | −64,000 | 3 | |
| Advances to suppliers | −18,000 | −19,000 | 186,000 | |
| Prepaid expenses and other current assets | 64,000 | 10,000 | −593,000 | |
| Other noncurrent assets | −42,000 | −117,000 | 17,000 | |
| Accounts payable | −76,000 | −607,000 | 326,000 | |
| Accrued expenses | 2 | −387,000 | 111,000 | |
| Operating lease liabilities | −709,000 | −631,000 | −966,000 | |
| Other current liabilities | 268,000 | −163,000 | 113,000 | |
| Deferred revenue | −2 | −1 | 249,000 | |
| Other noncurrent liabilities | 296,000 | −10,000 | 30,000 | |
| Net cash used in operating activities | −20 | −16 | −16 | |
| Acquisitions of property and equipment | −50,000 | −224,000 | 100,000 | |
| Purchase of short-term investments | −15 | −13 | 1 | |
| Proceeds from maturity of short-term investments | 18 | 1 | 1 | |
| Proceeds from sale of subsidiary interests | 7 | 0 | — | |
| Net cash (used in) provided by investing activities | 11 | −12 | −100,000 | |
| Proceeds from issuance of ordinary shares | 2 | 3 | 0 | |
| Capital contribution from noncontrolling interests | 3 | 20 | 0 | |
| Proceeds from loans | 286,000 | 4 | 0 | |
| Net cash provided by financing activities | 5 | 27 | 4,000 | |
| Effect of foreign exchange rate changes | 105,000 | −33,000 | −76,000 | |
| Net decrease in cash and cash equivalents | −4 | −2 | −17 | |
| Interest paid | 0 | 0 | 0 | |
| Interest received | 311,000 | 148,000 | 462,000 | |
| Income taxes paid | 2,000 | 7,000 | 36,000 | |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | 40,000 | 0 | — | |
| Issuance costs accrued in accrued expenses | 8,000 | 0 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro